Home

MARKSMAN HEALTHCARE COMMUNICATIONS | A DATA SCIENCE COMPANY

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Healthcare Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilise the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Medical Devices, Real World Data Curation and Healthcare Analytics”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Real World Evidence

Medical Affairs

Medical Devices

Evidence Curation

Healthcare Analytics

EMR Services

Competitive Intelligence

LATEST FROM BLOG

25Jul 2022

Randomized controlled trials (RCTs) are the mainstay of clinical research; it is estimated that about 18,000 RCTs are published each year. However, traditional RCTs usually take a long time to complete, are expensive, and the results are challenging to generalize to the real-world since they are derived under ideal conditions with strict inclusion and exclusion […]

21Jul 2022

Evidence from randomized clinical trials (RCTs) continues to be the standard reference point for treatment efficacy across the world. However, RCTs enrol patients based on strict inclusion and exclusion criteria, and hence RCT evidence is often not generalizable and inadequate for contributing to the day-to-day clinical practice decisions. Consequently, researchers are more interested in using […]

27Jun 2022

Concerns about the consistency of the post-marketing surveillance (PMS) for safety of medical devices is well known across the world. Only around 13% of post-marketing surveillance (PMS) clinical studies are completed on medical devices.[1] This is because new products or line extensions are launched frequently, even before full clinical trials of the parent device are […]

OUR REPRESENTATIONS

  • ISPOR 2022, May 15-18, Washington DC, USA

  • DIA 2022, June 19-23, Global Annual Meeting, Chicago, USA

  • ASCO 2022, June 3-7, Annual Meeting, Chicago, USA

  • 10X The Medical Device Conference 2022, May 10-12, California, USA

WHAT OUR CLIENT SAY